About Us  |   Advertise  |   Contact Us  |   Terms & Conditions  |   RSS Feeds
 
Support our sponsors:
sharemarket
NZX 50 Index 3330.18 3.40
S&P/ASX 200 4282.90 0.00
Dow Jones Industrials 12888.10 4.20

Slow recovery underpins Nuplex in key markets

Wednesday 9th June 2010

Text too small?

Nuplex reports gradual recovery across its main markets and expects to be able to increase prices to offset rising raw material prices.  

In an investor update presentation lodged with the NZX, Nuplex says its previous guidance of earnings before interest, tax, depreciation and amortisation remains on track for a record year at between $125 million and $135 million "largely driven by demand and some margin recovery."

Nuplex shares jumped 4.7% to $2.90 on the NZX and have dropped 16% in the past month.

After a horror year in 2008/09, caused by the triple whammy of high foreign debt, a weak kiwi dollar and the global recession, Nuplex reports interest costs will be "much lower" in the current financial year, and that capital expenditure needs are low until 2011, with a new executive team in place.

In its American markets, Nuplex says some recovery in demand is occuring, and that operations will be assisted by lower operating costs and gains from new technology.

In Asia, which continued to show strength last year, growth will continue but at a lower rate, and with some margin tightening, while in Australia market conditions are roughly the same as last year and lower operating costs will assist.

The New Zealand market is in "slow recovery phase". The domestic operation has high fixed costs that need to be addressed, with corporate costs - albeit under better control - exceeding operating profit.

Nuplex is "cautiously optimistic" about Europe, although that market could stall this year.

Businesswire.co.nz

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.
Bookmark and Share   Printable version
Related News

Nuplex enters Russian joint venture
Nuplex shares plunge 7.8% after profit warning
Nuplex gains regulatory approval for Viverso purchase
Nuplex may replace some bank debt with first issue of bonds in US private placement market
Nuplex to buy Bayer MaterialScience's Viverso, forecasts 10% earnings growth
Nuplex bows to shareholder pressure, withdraws director fee hike proposal
Nuplex directors ask for shareholders for 33% pay rise
Nuplex pays A$23.5 mln for Acquo Masterbatch
Nuplex full year profit up 7.5 pct
Daily ShareChat: Nuplex

Get quotes for Nuplex Industries Limited Ordinary Share (NPX)
NZX Annoucements for NPX
20 Jan 2012 JOINTV: NPX: Nuplex MOU to establish a Russian Joint Venture
20 Jan 2012 RELINT: NPX: DISCLOSURE NOTICE - OFFICER'S RELEVANT INTEREST
19 Jan 2012 RELINT: NPX: DISCLOSURE NOTICE - OFFICER'S RELEVANT INTEREST
16 Jan 2012 SSH: NPX: SSH Notice - ("ACC")
4 Jan 2012 GENERAL: NPX: Nuplex Completes Viverso Acquisition
 
Nuplex Industries Limited Ordinary Shares

Current quote:
NPX $2.61
Quotes delayed 20 minutes
Price when article published: $2.90

Previous News
FREE Email News
Breaking News 
After the Bell (daily) 

Unsubscribe/Update »

RSS feeds »
Twitter »
Facebook »

Stock Quote

Exchange: Stock Code:

Don't know the stock code? Search by keyword:

Today's Market Numbers
NZX 50 Index 3330.18 3.40
S&P/ASX 200 4282.90 0.00
Dow Jones Industrials 12888.10 4.20
Most Commented On
  forex centre
cfd centre
options centre
NZX 15 Index
AIA 2.47 -0.01
ANO 0.88 0.00
CEN 4.87 0.04
CNU 3.32 0.01
FBU 6.63 0.03
FPH 2.13 0.00
GMT 1.02 0.00
IFT 1.88 0.00
KIP 1.05 0.00
MFT 10.15 0.00
RYM 2.84 -0.01
SKC 3.52 0.00
SKT 5.10 0.02
TEL 2.17 0.01
VCT 2.60 -0.01

More market prices »

© Copyright 2012 Investment Research Group Ltd. All Rights Reserved.